299 related articles for article (PubMed ID: 15280184)
1. Reducing breast cancer incidence in familial breast cancer: overlooking the present panorama.
Marchetti P; Di Rocco CZ; Ricevuto E; Bisegna R; Cianci G; Calista F; Sidoni T; Porzio G; Ficorella C
Ann Oncol; 2004; 15 Suppl 1():I27-I34. PubMed ID: 15280184
[TBL] [Abstract][Full Text] [Related]
2. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis.
Grann VR; Jacobson JS; Whang W; Hershman D; Heitjan DF; Antman KH; Neugut AI
Cancer J Sci Am; 2000; 6(1):13-20. PubMed ID: 10696733
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.
King MC; Wieand S; Hale K; Lee M; Walsh T; Owens K; Tait J; Ford L; Dunn BK; Costantino J; Wickerham L; Wolmark N; Fisher B;
JAMA; 2001 Nov; 286(18):2251-6. PubMed ID: 11710890
[TBL] [Abstract][Full Text] [Related]
4. Management updates for women with a BRCA1 or BRCA2 mutation.
Nusbaum R; Isaacs C
Mol Diagn Ther; 2007; 11(3):133-44. PubMed ID: 17570734
[TBL] [Abstract][Full Text] [Related]
5. Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis.
Grann VR; Jacobson JS; Thomason D; Hershman D; Heitjan DF; Neugut AI
J Clin Oncol; 2002 May; 20(10):2520-9. PubMed ID: 12011131
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen and risk of contralateral breast cancer among women with inherited mutations in BRCA1 and BRCA2: a meta-analysis.
Xu L; Zhao Y; Chen Z; Wang Y; Chen L; Wang S
Breast Cancer; 2015 Jul; 22(4):327-34. PubMed ID: 26022977
[TBL] [Abstract][Full Text] [Related]
7. [Breakthrough in breast cancer chemoprevention].
Kahán Z; Thurzó L
Orv Hetil; 2003 Mar; 144(13):597-603. PubMed ID: 12728784
[TBL] [Abstract][Full Text] [Related]
8. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
[TBL] [Abstract][Full Text] [Related]
9. Chemoprevention options for BRCA1 and BRCA2 mutation carriers.
Eeles RA; Powles TJ
J Clin Oncol; 2000 Nov; 18(21 Suppl):93S-9S. PubMed ID: 11060334
[TBL] [Abstract][Full Text] [Related]
10. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.
Narod SA; Brunet JS; Ghadirian P; Robson M; Heimdal K; Neuhausen SL; Stoppa-Lyonnet D; Lerman C; Pasini B; de los Rios P; Weber B; Lynch H;
Lancet; 2000 Dec; 356(9245):1876-81. PubMed ID: 11130383
[TBL] [Abstract][Full Text] [Related]
12. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.
Metcalfe KA; Birenbaum-Carmeli D; Lubinski J; Gronwald J; Lynch H; Moller P; Ghadirian P; Foulkes WD; Klijn J; Friedman E; Kim-Sing C; Ainsworth P; Rosen B; Domchek S; Wagner T; Tung N; Manoukian S; Couch F; Sun P; Narod SA;
Int J Cancer; 2008 May; 122(9):2017-22. PubMed ID: 18196574
[TBL] [Abstract][Full Text] [Related]
13. Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature.
Calderon-Margalit R; Paltiel O
Int J Cancer; 2004 Nov; 112(3):357-64. PubMed ID: 15382059
[TBL] [Abstract][Full Text] [Related]
14. [Genetic test and prophylactic treatment in breast cancer families].
Miyoshi Y; Noguchi S
Gan To Kagaku Ryoho; 2002 Apr; 29(4):512-22. PubMed ID: 11977534
[TBL] [Abstract][Full Text] [Related]
15. Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial.
Pujol P; Lasset C; Berthet P; Dugast C; Delaloge S; Fricker JP; Tennevet I; Chabbert-Buffet N; This P; Baudry K; Lemonnier J; Roca L; Mijonnet S; Gesta P; Chiesa J; Dreyfus H; Vennin P; Delnatte C; Bignon YJ; Lortholary A; Prieur F; Gladieff L; Lesur A; Clough KB; Nogues C; Martin AL;
Fam Cancer; 2012 Mar; 11(1):77-84. PubMed ID: 22076253
[TBL] [Abstract][Full Text] [Related]
16. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
17. Chemoprevention of breast cancer.
Osborne MP
Surg Clin North Am; 1999 Oct; 79(5):1207-21. PubMed ID: 10572559
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen and breast cancer risk in women harboring a BRCA1 germline mutation: computed efficacy, effectiveness and impact.
Eisinger F; Charafe-Jauffret E; Jacquemier J; Birnbaum D; Julian-Reynier C; Sobol H
Int J Oncol; 2001 Jan; 18(1):5-10. PubMed ID: 11115532
[TBL] [Abstract][Full Text] [Related]
19. The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation.
Metcalfe KA; Snyder C; Seidel J; Hanna D; Lynch HT; Narod S
Fam Cancer; 2005; 4(2):97-103. PubMed ID: 15951959
[TBL] [Abstract][Full Text] [Related]
20. Preventive surgery is associated with reduced cancer risk and mortality in women with BRCA1 and BRCA2 mutations.
Domchek SM; Rebbeck TR
LDI Issue Brief; 2010; 16(2):1-4. PubMed ID: 21545057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]